Mar 24Accession Therapeutics awarded €7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy
Jan 9Drug Discovery World features Dave Cole discussing challenges and advances in re-engineering oncolytic immunotherapy
Dec 4, 2025Accession Therapeutics raises £30.5 million ($40 million USD) to advance TROCEPT immunotherapy platform
Nov 17, 2025Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy
Oct 17, 2025Accession Therapeutics presents first-in-human ATTEST trial at the European Society for Medical Oncology (ESMO) Congress 2025
Sep 4, 2024Accession Therapeutics submits CTA to the UK MHRA to start Phase 1 first-in-human clinical trial with lead TROCEPT anti-cancer immunotherapy
Apr 25, 2024Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Jul 19, 2023Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trials
Jan 4, 2023Accession Therapeutics presented some of the exciting preclinical data for our lead programme
